CRIS vs DBVT

Curis, Inc. vs DBV Technologies S.A. — Valuation Comparison 2026

CRIS

Biological Products, (No Diagnostic Substances)
Curis, Inc.
Quality
5.0
out of 10
Value Trap
39
LOW
Price
$0.57
Last close
Models
9/13
Active
VS

DBVT

Biological Products, (No Diagnostic Substances)
DBV Technologies S.A.
Quality
4.9
out of 10
Value Trap
32
LOW
Price
$19.10
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType CRIS Fair ValueCRIS Upside DBVT Fair ValueDBVT Upside
Bayesian DCF Intrinsic $0.25 -56.7% $6.94 -63.7%
First Chicago Scenario $0.33 -41.9% $0.78 -95.8%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.78 +389.6% $6.78 -64.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRIS vs DBVT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRIS vs DBVT — Which Stock Is More Undervalued?

CRIS scores higher with a 5.0/10 quality rating vs DBVT's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Curis, Inc. (CRIS) and DBV Technologies S.A. (DBVT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRIS currently trades at $0.57 with a QOC of 5.0/10, while DBVT trades at $19.10 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).